pr_newswire_finance · 2026-10-23
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha radiotherapy offers a differentiated approach through a target distinct from...
Sector coverage: Healthcare · Biotechnology
Read the original at pr_newswire_finance ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。